Inventor · disambiguated record
David Satijn
Also filed as: SATIJN DAVID · SATIJN DAVID P E
46 granted patents·47 pending applications·316 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
93 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0398US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0498US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0597US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 0697US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 0797US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0897US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0997US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 1096US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 1196US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 1296US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1396US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1495US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 1595US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 1695US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 1793US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 1893US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 1993US7267965B2Means and methods for regulating gene expressionCHROMAGENICS BV·Filed 2004·Granted Sep 11, 2007·30 cites·11 claims
- 2092US9168314B2Human antibody drug conjugates against tissue factorSATIJN DAVID·Filed 2011·Granted Oct 27, 2015·29 cites·11 claims
- 2191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 2290US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 2390US9862769B2Monoclonal antibodies against HER2DE GOEIJ BART·Filed 2011·Granted Jan 9, 2018·16 cites·42 claims
- 2490US9714294B2Monoclonal antibodies against HER2 epitopeDE GOEIJ BART·Filed 2011·Granted Jul 25, 2017·17 cites·43 claims
- 2590US9714297B2Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2015·Granted Jul 25, 2017·9 cites·29 claims
- 2690US9150658B2Human antibodies against tissue factor and methods of use thereofVERPLOEGEN SANDRA·Filed 2009·Granted Oct 6, 2015·20 cites·43 claims
- 2789US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 2888US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 2987US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
- 3087US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 3186US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 3286US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 3386US2024294661A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2023·Application pending·0 cites
- 3485US11046771B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Jun 29, 2021·2 cites·23 claims
- 3585US7794977B2Means and methods for regulating gene expressionCHROMAGENICS BV·Filed 2007·Granted Sep 14, 2010·4 cites·18 claims
- 3685US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 3785US2023312693A1Agents, Uses and Methods for the Treatment of SynucleinopathyH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 3882US10968280B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2020·Granted Apr 6, 2021·1 cites·12 claims
- 3982US2023089969A1Multispecific antibodies against cd40 and cd137GENMAB AS·Filed 2022·Application pending·0 cites
- 4082US2023416403A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 4180US11091553B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Aug 17, 2021·1 cites·20 claims
- 4279US12410258B2Antibodies capable of binding to OX40, variants thereof and uses thereofGENMAB AS·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 4379US10793640B2Monoclonal antibodies against HER2 epitopeGENMAB AS·Filed 2017·Granted Oct 6, 2020·1 cites·38 claims
- 4479US2025340669A1Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 4577US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 4677US2024317881A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2024·Application pending·0 cites
- 4776US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 4876US2020171152A1Antibodies binding axlGENMAB AS·Filed 2019·Application pending·0 cites
- 4976US2022411522A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 5075US12351650B2Antibodies binding to fibroblast activation protein alpha and death receptor 4GENMAB AS·Filed 2024·Granted Jul 8, 2025·0 cites·34 claims
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Satijn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →